about
Overexpression of Ras-GTPase-activating protein SH3 domain-binding protein 1 correlates with poor prognosis in gastric cancer patients.Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.Notch1 activation is a poor prognostic factor in patients with gastric cancer.Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer.A CD44-specific peptide, RP-1, exhibits capacities of assisting diagnosis and predicting prognosis of gastric cancer.Effect of 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid in combination with carboplatin on gastric carcinoma growth in vivoLinked read sequencing resolves complex genomic rearrangements in gastric cancer metastases.Efficacy of a hypotonic treatment for peritoneal dissemination from gastric cancer cells: an in vivo evaluationMetastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer.Acute hiatal hernia: a late complication following gastrectomy.Low CA II expression is associated with tumor aggressiveness and poor prognosis in gastric cancer patientsUpregulated expression of C-X-C chemokine receptor 4 is an independent prognostic predictor for patients with gastric cancer.Identification and characterization of CDH1 germline variants in sporadic gastric cancer patients and in individuals at risk of gastric cancer.Therapeutic effects of lentivirus-mediated shRNA targeting of cyclin D1 in human gastric cancer.The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients.Downregulation of long noncoding RNA ZMAT1 transcript variant 2 predicts a poor prognosis in patients with gastric cancer.Non-invasive imaging of implanted peritoneal carcinomatosis in mice using PET and bioluminescence imaging.Postoperative chemotherapy in gastric cancer, consisting of etoposide, doxorubicin and cisplatin, followed by radiotherapy with concomitant cisplatin: A feasibility study.Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer.Regulation of osmolality for cancer treatment.Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer.Decreased expression of Calpain-9 predicts unfavorable prognosis in patients with gastric cancer."Magic" of our gastric cancer results on perioperative chemotherapy.Elevated Expression of Calpain-4 Predicts Poor Prognosis in Patients with Gastric Cancer after Gastrectomy.High Hepsin expression predicts poor prognosis in Gastric Cancer.Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma.Gastric cancer-molecular and clinical dimensions.Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer.CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patientsManagement strategies for locoregional recurrence in early-stage gastric cancer: retrospective analysis and comprehensive literature review.Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR.Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis.Honokiol confers immunogenicity by dictating calreticulin exposure, activating ER stress and inhibiting epithelial-to-mesenchymal transition.Effects of legumain as a potential prognostic factor on gastric cancers.Downregulation of Skp2 inhibits the growth and metastasis of gastric cancer cells in vitro and in vivo.ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo.Basal renal function reserve and mean kidney dose predict future radiation-induced kidney injury in stomach cancer patients.Lentivirus-delivered Krüppel-like factor 8 small interfering RNA inhibits gastric cancer cell growth in vitro and in vivo.177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.P53 and Protein Phosphorylation Regulate the Oncogenic Role of Epithelial Cell Transforming 2 (ECT2).
P2860
Q30009198-193F32B4-F4AC-4924-BEC5-BA66C2467ED9Q33378937-01B78347-4111-45F5-8019-F286572A1E99Q33555227-FE1EC752-9C2D-4DB4-8AD9-F196636F7D86Q33672879-DF24823C-A256-4038-A67B-7ECDB53AA4AEQ33728237-018F0E52-AC22-46AB-B2B7-5C23DD41E9B4Q33787907-0BACC384-8CFB-41F8-829D-9A86C159F46FQ33815218-3383E6C2-3890-4E85-A831-D6F3F2FE45BAQ33908921-A9E28060-174D-4A4F-8F60-834305A962C7Q34091425-CCB9B87F-BD75-4E36-B93B-A79ABF2944FCQ34220599-9BD7DF0D-5BB0-4DB4-83BA-FBCA5A4BA1E0Q34501774-14C63B57-D1A9-4A33-BE12-28DA694FDED2Q34927102-6371BAA5-DF92-458B-BFC4-BC5D5181497EQ35034978-7072C977-5D99-4583-888B-B3E4B4D0C367Q35117351-BCE52637-8BAA-4B25-90CE-503CFFF9173EQ35819575-662CBB04-4250-4361-B49C-C9C67AFA45A7Q35854266-87867FF5-630E-45AE-977E-711033C32938Q36025789-A79D2FFF-B157-455B-85ED-4FAB1E2F421AQ36076046-4B0D4EB3-595F-4D43-A2FD-A1D7F5352025Q36216932-616C7DA8-A4DE-4379-88F6-C275E0CF442EQ36276348-BFA0AD30-CCB5-4233-9E08-911639DA6318Q36500558-CB40ED5D-EE2B-4F14-BDBA-943D1558117EQ37087283-F9D9D646-EB6C-48C0-BF89-86EB93436240Q37168795-5A7CB620-1945-41C9-BF18-89FCA1C1095FQ37377194-1C64C318-BD69-4441-9EC4-8A3EDD8BF8DFQ37411864-278145A4-C4F0-4AB3-BAF3-CF83315C5EB9Q37541524-F30A7DD8-E6C8-45BB-BBEC-0863C80A29F4Q37591176-E43F464F-DAEC-4A37-8753-2F432499C258Q37711697-B95FF772-4B92-4B3F-8AF6-6C1184791412Q37746314-2B3F9C36-4561-45B6-8AA3-3BBDC4F0C634Q37787914-6B7B9AD0-62C5-42D1-951E-BABBD1778405Q38406148-82A50283-D6DA-4A3D-A62F-BA068AA07EC5Q38452866-0477F995-277D-4E69-9F90-D299E13CAB49Q38916710-1D029796-A4A2-4CBF-98DA-BAB46FBD2308Q39143545-CFF45649-3AB2-44CE-B475-9BCC43A950E1Q39228469-FA98BA72-9C44-40F4-8AC9-C26439344FB3Q39280369-158BDAC9-ED1E-405F-947A-207D200F9EAAQ39320198-E1B683C9-7D98-451C-ABCE-B2793FBA87F5Q39443486-07A3FCFB-BF18-4CA9-BC1B-3A0351F6E179Q39632700-D462210B-7179-4205-84E3-53ABDC221C9FQ40959318-8FE2EAEA-5FF8-4985-AFE0-CA103C232EA1
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Adjuvant therapy in gastric cancer.
@ast
Adjuvant therapy in gastric cancer.
@en
type
label
Adjuvant therapy in gastric cancer.
@ast
Adjuvant therapy in gastric cancer.
@en
prefLabel
Adjuvant therapy in gastric cancer.
@ast
Adjuvant therapy in gastric cancer.
@en
P2093
P356
P1476
Adjuvant therapy in gastric cancer.
@en
P2093
G Bruce Mann
Lionel Lim
Michael Michael
Trevor Leong
P304
P356
10.1200/JCO.2005.11.593
P407
P577
2005-09-01T00:00:00Z